

LAW OFFICES  
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.  
1300 I Street, NW  
Washington, DC 20005

Telephone  
(202) 408-4000

Facsimile  
(202) 408-4400

**FACSIMILE TRANSMITTAL**

**TO**

Name: Examiner S. Kaushal  
Firm: U.S. Patent and Trademark Office  
Fax No.: 703-746-3124  
Phone No.: 703-305-6838  
Subject: USSN 09/244,130  
Our Ref.: 03495.0111-10000


**FROM**

Name: Salvatore J. Arrigo  
Phone No.: 202-408-4160  
Fax # Verified by: K. Smith/MD820  
# Pages (incl. this): 5  
Date: February 5, 2003

Confirmation Copy to Follow: Yes  No

**Certification of Facsimile Transmission**

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

  
Salvatore J. Arrigo, Reg. No. 46,063

Dated: February 5, 2003

Examiner: S. Kaushal - Fax No.: (703) 746-3124

If there is a problem with this transmission, notify fax room at (202) 408-4174 or the sender at the number above.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

#30/E  
Tute  
2/5/03PATENT  
Attorney Docket No. 3495.0111-10  
Customer No. 22,852

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernard DUJON et al.

Serial No.: 09/244,130

Filed: February 4, 1999

Group Art Unit: 1636

Examiner: KAUSHAL, S.

For: NUCLEOTIDE SEQUENCE ENCODING  
THE ENZYME I-SCEI AND THE USES THEREOFCommissioner for Patents  
Washington, D.C. 20231

Sir:

SUPPLEMENTAL AMENDMENT

Applicants filed an RCE on November 26, 2002. Applicants submit the following supplemental amendments and remarks. Please amend this application as follows:

IN THE CLAIMS:

Please cancel claims 53-86.

Please add the following new claims:

94. (NEW) A transgenic mouse comprising a recombinant cell, wherein said cell comprises a nucleotide sequence, wherein said nucleotide sequence comprises a Group I intron encoded endonuclease recognition site,

wherein the site is selected from the group consisting of an I-SceIV site, an I-CsmI site, I-PanI site, I-SceII site, an I-CeuI site, an I-PpoI site, an I-SceIII site, an I-CreI site, an I-TevI site, an I-TevII site, an I-TevIII site, and an I-SceI site.

95. (NEW) The transgenic mouse of claim 94, wherein the site is an I-SceIV site.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP  
1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com